The global bronchitis treatment market is anticipated to grow at a considerable CAGR of 4.7% during the forecast period. Bronchitis is a non-communicable disease, generally caused due to pollution, smoking, bacterial infections, and dust or toxic gases in the environment. Cigarettes smoking is the prominent cause of bronchitis, and its increasing prevalence is likely to boost the market growth. In 2018, 9.0 million adults, or 3.6% of those ages 18 or older, had chronic bronchitis. According to information provided by the Center for Disease Control and Prevention, in May 2020, more than 16 million Americans are living with a disease caused by smoking, for every person who dies because of smoking, at least 30 people live with a serious smoking-related illness. Moreover, cigarette smoking is responsible for more than 480,000 deaths per year in the US, and if the smoking continues at the current rate among the youth, around 5.6 million Americans younger than 18 years, are expected to die prematurely from smoking-related problems.
Get Free Sample link @ https://www.omrglobal.com/request-sample/bronchitis-treatment-market
In addition, factors such as rising levels of chemical pollutants, gastric reflux, and the risk associated with smoking such as lung, bronchus, and trachea cancer, and growing awareness of COPD in the general population in emerging economies is also a favorable trend in the expansion of the global bronchitis treatment market.
A full report of Global Bronchitis Treatment Market available @ https://www.omrglobal.com/industry-reports/bronchitis-treatment-market
- Market Coverage
- Market number available for – 2022-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered- By Source, By Product Type, By Applications
- Competitive Landscape- Archer Daniels Midland Co., Ingredion Inc., Kerry Group Plc, Cargill Inc., and others
Market Segmentation
Global Bronchitis Treatment Market by Type
- Drugs
- Antibiotics
- Anti-inflammatory drugs
- Bronchodilators
- Others (Mucolytics)
- Oxygen Therapy
Regional Analysis
- North America
- United States
- Canada
- Europe
- UK
- Germany
- Italy
- Spain
- France
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- Rest of Asia-Pacific
- Rest of the World
Company Profiles
- Abbott Laboratories
- Aurobindo Pharma Ltd.
- Bayer AG
- Boehringer Ingelheim International GmbH
- Cipla Ltd.
- Dr Reddy’s Laboratories Ltd.
- GlaxoSmithKline PLC
- Lupin Pharmaceuticals, Inc.
- Mayne Pharma Group Ltd.
- Merck & Co., Inc.
- Mucinex (Reckitt Benckiser Group plc)
- Novartis AG
- Pfizer Inc.
- Sanofi SA
- Teva Pharmaceutical Industries Ltd.
The Report Covers
- Market value data analysis of 2022 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global bronchitis treatment market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/bronchitis-treatment-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 780-304-0404
